Monitor the merger closing on November 6, 2026, and the subsequent trading of the combined entity under the new name Avenzo Therapeutics. The reverse stock split ratio (1-for-2 to 1-for-9) has not yet been finalized and will be mutually determined by Rallybio and Avenzo.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 4 $15.69entry
- T+1 · yesterday +0.38%α +0.07% · $15.75
- T+2 · todayOpen
- T+5 · in 4d Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Rallybio Corp held its annual meeting on November 4, 2026, where stockholders approved all eight proposals related to the pending merger with Avenzo Therapeutics, including the issuance of shares representing more than 20% of outstanding stock (change of control), a reverse stock split (1-for-2 to 1-for-9), a name change to Avenzo Therapeutics, an increase in authorized shares from 200M to 500M, and the adoption of post-merger equity plans. Separately, the company announced a special cash distribution of $83.6 million ($13.90 per share) to stockholders, with the merger expected to close on November 6, 2026.
Key Facts
- Stockholders approved issuance of shares representing >20% of outstanding stock and resulting in change of control (Proposal 1: 4,506,703 for, 15,979 against).
- Stockholders approved reverse stock split in range of 1-for-2 to 1-for-9 (Proposal 2: 4,768,828 for, 21,477 against).
- Stockholders approved name change to Avenzo Therapeutics, Inc. (Proposal 3: 4,770,644 for, 19,661 against).
- Stockholders approved increase in authorized shares from 200,000,000 to 500,000,000 (Proposal 4: 4,275,569 for, 245,991 against).
- Stockholders approved Avenzo 2026 Equity Incentive Plan (Proposal 7: 3,564,394 for, 958,257 against) and 2026 Employee Stock Purchase Plan (Proposal 8: 3,760,074 for, 752,717 against).
- Board declared a special cash distribution of $83.6 million ($13.90 per share) in connection with the merger, payable to holders of record as of November 5, 2026.
- Merger expected to close on November 6, 2026, subject to satisfaction or waiver of outstanding conditions.
- As of the record date (September 11, 2026), 5,312,584 shares were outstanding; 4,790,320 shares were represented at the meeting.
Financial Impact
Special cash distribution of $83.6 million ($13.90 per share) to be paid to stockholders and pre-funded warrant holders; the distribution exceeds 25% of the stock price on the declaration date, triggering Nasdaq due bill procedures.
Risk Factors
- Merger closing is subject to satisfaction or waiver of outstanding conditions; risk of delay or failure to close.
- Concurrent private placement financing contemplated by the merger agreement may not be consummated.
- Holders of contingent value rights to be issued in connection with the merger may never receive any proceeds.
- The reverse stock split ratio has not been determined; final ratio could affect post-merger share price and liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-447550 |
| Document: 0001193125-26-447550-index-headers.html | 0001193125-26-447550 |
| Document: 0001193125-26-447550-index.html | 0001193125-26-447550 |
| Document: 0001193125-26-447550.txt | 0001193125-26-447550 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 6, 2026 today | 425 | $15.73 | awaiting T+60 | awaiting T+60 | $15.75 (−0.13%) |
Nov 6, 2026 today | 8-K | $15.73 | awaiting T+60 | awaiting T+60 | $15.75 (−0.13%) |
Nov 4, 2026 2d ago | 8-K | $15.69 | awaiting T+60 | awaiting T+60 | $15.75 (+0.38%) |
Oct 26, 2026 11d ago | 425 | $15.93 | awaiting T+60 | awaiting T+60 | $15.75 (−1.13%) |
Oct 26, 2026 11d ago | 8-K | $15.93 | awaiting T+60 | awaiting T+60 | $15.75 (−1.13%) |
Oct 16, 2026 21d ago | EFFECT | $16.28 | awaiting T+60 | awaiting T+60 | $15.75 (−3.26%) |
Oct 14, 2026 23d ago | S-4/A | $16.78 | awaiting T+60 | awaiting T+60 | $15.75 (−6.11%) |
Jul 15, 2026 16w ago | S-4 | $15.96 $17.02 | ▲ +6.64% | ▲ +2.93% | $15.75 (−1.32%) |
Jun 1, 2026 22w ago | 425 | $16.87 $16.89 | ▲ +0.09% | ▼ −1.14% | $15.75 (−6.64%) |
Jun 1, 2026 22w ago | 8-K | $16.87 $16.89 | ▲ +0.09% | ▼ −1.14% | $15.75 (−6.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers